XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $907K invested in XTL Biopharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.65% less ownership
Funds ownership: 4.18% → 3.53% (-0.65%)
31% less capital invested
Capital invested by funds: $1.31M → $907K (-$407K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$76.5K |
| 2 |
Morgan Stanley
New York
|
+$2.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$271K |
XTLB Hedge Fund Activity: Q3 2016 in Review
5 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2016, worth a combined $907K — down 31% from $1.31M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $76.5K. The largest seller was Sabby Management, cutting an estimated $271K.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2016, up from 4 in Q2 2016.
- Funds reported $907K of XTL Biopharmaceuticals stock for Q3 2016, down 31% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $76.5K added.
- The largest XTL Biopharmaceuticals seller in Q3 2016 was Sabby Management, an estimated $271K sold.
Based on aggregated 13F filings for Q3 2016.